Compliance & Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.
Editorial policy
Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.
ARA-290 is a 15-amino acid synthetic peptide derived from erythropoietin (EPO) that activates the innate repair receptor (IRR), a newly identified signaling pathway distinct from classical EPO erythropoietic activity. Rather than stimulating red blood cell production, ARA-290 activates cellular repair and cytoprotection mechanisms, showing particular promise for neuropathic pain relief, diabetic peripheral neuropathy, and tissue protection without the risks associated with EPO. Research suggests ARA-290 may work through JAK2/STAT5 and PI3K/Akt signaling to enhance cellular stress resistance and reduce pain signaling.
Research context only. The peptides discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
Quick Answer: ARA-290 is an erythropoietin-derived peptide that activates the innate repair receptor to promote tissue protection and pain relief without erythropoietic effects. Primary research focuses on neuropathic pain, diabetic neuropathy, and cellular cytoprotection. Dosing is typically 2–4 mg subcutaneous 2–3 times weekly, with pain relief appearing within days to weeks.
What Is ARA-290?
ARA-290 is a synthetic 15-amino acid peptide that was developed by Araim Pharmaceuticals (hence the "ARA" designation) as a therapeutic derived from erythropoietin (EPO). EPO is well-known for stimulating red blood cell production through the classical EPO receptor (EPOR) pathway, but ARA-290 represents a discovery-driven breakthrough: it activates a distinct pathway, the innate repair receptor (IRR), that confers cellular cytoprotection and tissue repair without triggering erythropoiesis.
The key innovation is pathway selectivity. EPO can activate two distinct pathways: the classical EPOR pathway (which drives RBC production, increases viscosity, and carries risks of thrombosis) and the newer IRR pathway (which triggers cytoprotection, inflammation reduction, and tissue repair). ARA-290 is designed to activate IRR specifically, delivering EPO's protective and repair benefits while circumventing the systemic hematologic effects and associated risks of full EPO activation.
This selectivity makes ARA-290 fundamentally different from EPO itself. While EPO use in athletes is banned due to increased hematocrit and thrombosis risk, ARA-290 offers tissue repair and pain relief without hematocrit elevation — a major advance for pain and neuroprotection research.
The Innate Repair Receptor (IRR) and Cytoprotective Mechanisms
The innate repair receptor is a heterodimeric receptor composed of the β-common receptor (βcR, also CD131) and EPOR in a specific configuration distinct from the classical EPOR homodimer. This IRR pathway triggers a distinct intracellular signaling cascade:
- JAK2/STAT5 signaling: ARA-290 activates STAT5 phosphorylation via JAK2, triggering gene expression of anti-apoptotic proteins (Bcl-2, Bcl-xL), heat shock proteins, and stress-response genes
- PI3K/Akt pathway: Parallel activation of phosphoinositide 3-kinase and Akt/PKB, promoting cell survival and mitochondrial protection
- MAPK/ERK signaling: Moderate activation of MAPK/ERK cascade, contributing to cytoprotection without massive proliferation
- NF-κB modulation: Complex effects on NF-κB signaling that favor anti-inflammatory outcomes in some contexts
The net result is enhanced cellular stress resistance: cells exposed to ARA-290 show improved viability under ischemia, hypoxia, oxidative stress, and inflammatory insult. This "cytoprotective" effect is the foundation for ARA-290's therapeutic potential in tissue-damaging conditions.
ARA-290 for Neuropathic Pain and Diabetic Neuropathy
The most extensively researched application of ARA-290 is neuropathic pain relief, particularly in diabetic peripheral neuropathy (DPN) — a major complication of diabetes affecting roughly 50% of diabetic patients. DPN is characterized by pain, numbness, and sensory loss in the feet and legs, with limited effective treatments.
Mechanism in neuropathic pain: Neuropathic pain results from damage to peripheral sensory neurons and altered pain signaling in dorsal root ganglia and spinal cord. Hyperglycemia, oxidative stress, and neuroinflammation drive this damage. ARA-290's IRR activation provides neuroprotection through: (1) reducing neuronal apoptosis, (2) improving mitochondrial function in neurons, (3) reducing neuroinflammatory cytokine production, and (4) modulating pain-signaling pathways in spinal cord and dorsal root ganglia.
Clinical research highlights: The most notable study (Brines et al., 2015, in Diabetes Care) showed that ARA-290 significantly reduced neuropathic pain symptoms in type 1 and type 2 diabetic patients with DPN. Patients receiving ARA-290 reported reduced pain intensity, improved sensory thresholds, and improved small fiber nerve density (a marker of nerve regeneration) compared to placebo. This is particularly remarkable because neuropathic pain is notoriously difficult to treat and DPN typically progresses despite current therapies.
Mechanism of pain relief: ARA-290 likely works through multiple mechanisms: reducing neuroinflammatory mediators, improving mitochondrial ATP production in damaged neurons, reducing neuronal apoptosis, and potentially modulating pain-gate signaling in spinal cord dorsal horn neurons. The rapid onset of pain relief (within days) suggests modulation of inflammatory and neuronal dysfunction rather than true nerve regeneration, though long-term studies suggest some regenerative capacity as well.
Other Neuropathic Pain Conditions
While diabetes-associated DPN is the most studied, ARA-290 shows promise in other neuropathic pain states including:
Chemotherapy-induced peripheral neuropathy (CIPN): Cancer patients treated with neurotoxic chemotherapy agents (taxanes, vinca alkaloids, platinum agents) develop dose-limiting CIPN. ARA-290 may protect sensory neurons from chemotherapy-induced damage and accelerate recovery, though clinical data is still emerging.
Metabolic neuropathies: Uremia, hypothyroidism, and other metabolic states causing neuropathic pain may respond to ARA-290's neuroprotective mechanisms.
Post-herpetic neuralgia (PHN): Chronic pain following herpes zoster infection is notoriously difficult to treat. ARA-290's anti-inflammatory and neuroprotective effects may address underlying neuroinflammation driving PHN.
Small fiber neuropathy: Idiopathic and systemic conditions affecting small fiber neurons (A-delta and C fibers) may benefit from ARA-290's ability to improve small fiber density and function.
Tissue Protection Without Erythropoietic Effects
A critical advantage of ARA-290 over EPO is the complete absence of erythropoietic activity. Full EPO activation increases hemoglobin and hematocrit, which increases blood viscosity and carries significant risks of:
Safety advantage: ARA-290 does not increase hemoglobin, hematocrit, or red blood cell count. No thrombosis risk, no polycythemia, no need for phlebotomy. This makes it suitable for long-term use without the systemic complications of EPO.
- Thrombosis (DVT, PE, stroke, MI)
- Polycythemia-induced hypertension
- Erythropoiesis-stimulating agent (ESA) complications in chronic kidney disease
- Doping concerns in athletics
In clinical trials, ARA-290 does not increase hemoglobin, hematocrit, or platelet count. Blood pressure remains stable. No thrombotic events have been documented in neuropathy trials. This clean safety profile makes ARA-290 a viable long-term therapeutic without the systemic risks that have limited EPO use.
ARA-290 Dosage and Administration
Administration route: ARA-290 is administered exclusively via subcutaneous injection. The standard protocol uses injections 2–3 times per week (e.g., Monday, Wednesday, Friday or Monday, Thursday). Bioavailability is high via subcutaneous route with relatively long half-life (~4–6 hours), allowing twice or thrice-weekly dosing.
Onset of action: Pain relief is often rapid — within 24–72 hours of the first injection. This is notably faster than most pain medications (which take weeks). Full benefit may require 4–8 weeks of consistent dosing, with optimal effects at 12+ weeks.
Cycle length: Most clinical protocols use 12–16 week treatment periods, with subsequent breaks or dose reduction to maintenance levels. Long-term continuous use hasn't been extensively studied; cycling is a conservative approach until more human data emerges.
Sarcoidosis Research and Innate Immunity
Beyond neuropathic pain, ARA-290 is being researched for sarcoidosis — a multisystem inflammatory disorder characterized by granuloma formation in lungs, skin, eyes, and other organs. Sarcoidosis involves dysregulated innate immunity with excessive granulomatous inflammation and TNF-alpha production.
Mechanism in sarcoidosis: ARA-290's IRR activation may suppress excess TNF-alpha and other pro-inflammatory mediators, reducing granulomatous inflammation and improving symptoms. Early studies suggest ARA-290 may improve pulmonary function, reduce systemic inflammation, and improve fatigue and pain symptoms in sarcoidosis patients.
Broader implications: This line of research highlights ARA-290's potential beyond neuropathy — as a general anti-inflammatory and cytoprotective agent for conditions involving excessive innate immune activation and tissue damage.
Side Effects and Safety Profile
ARA-290 has demonstrated a favorable safety profile in clinical trials with minimal adverse effects at therapeutic doses.
Most common observations: Injection site reactions (mild erythema, swelling) are the most frequently reported side effect, typically mild and transient. Headache, flu-like symptoms, and mild transient fever have been reported in a small percentage of subjects, typically in the first 24–48 hours after injection — possibly reflecting an initial immune response.
Serious adverse events: No serious adverse events directly attributable to ARA-290 have been documented in published trials. No thrombosis, no hematologic abnormalities, no organ toxicity. Blood pressure, renal function, and liver function remain stable.
No erythropoietic complications: No elevation in hemoglobin, hematocrit, platelets, or RBC count, eliminating the thrombosis and polycythemia risks associated with full EPO activation.
Tolerability: Most subjects tolerate ARA-290 well with good compliance and minimal dropout due to side effects. The rapid onset of pain relief (within days) often outweighs the minor injection site reactions.
ARA-290 vs. Other Neuropathy Treatments
Mechanism advantage: Traditional neuropathy treatments (gabapentin, pregabalin, duloxetine) modulate pain signaling but don't address underlying neurotoxicity. ARA-290 promotes actual neuroprotection and potential nerve repair, representing a novel therapeutic mechanism.
vs. Gabapentin/Pregabalin: These GABA-analogs suppress pain signaling but don't address nerve damage. ARA-290 works at the cellular level to protect neurons and reduce underlying inflammation. Many find ARA-290's mechanism more appealing — treating the cause rather than just suppressing symptoms.
vs. Duloxetine/SNRIs: Serotonin-norepinephrine reuptake inhibitors modulate mood and pain perception. ARA-290 is mechanism-distinct — pure cellular cytoprotection without CNS effects. May be additive or complementary.
vs. Alpha-lipoic acid and other antioxidants: ALA and antioxidants provide some neuroprotection, but ARA-290's IRR pathway activation is more comprehensive, targeting multiple cytoprotective and anti-inflammatory mechanisms simultaneously.
Trusted Research-Grade Sources
Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).
Particle Peptides
Independently HPLC-tested, transparent COAs, comprehensive product range.
Browse Particle Peptides →Limitless Life Nootropics
Premium research peptides with strong customer support and verified purity.
Browse Limitless Life →Frequently Asked Questions
ARA-290 activates the innate repair receptor (IRR) to provide neuroprotection, reduce inflammation, and enhance cellular cytoprotection. It relieves neuropathic pain (especially diabetic neuropathy), supports tissue protection without erythropoietic effects, and may improve small fiber nerve density and regeneration.
Pain relief typically begins within 24–72 hours of the first injection — notably faster than traditional neuropathy medications. Full benefit with optimal pain reduction and nerve regeneration markers develops over 4–8 weeks. This rapid onset is one of ARA-290's distinguishing features.
No. ARA-290 is specifically designed to activate the innate repair receptor (IRR) without activating the classical EPO receptor that drives RBC production. No increase in hemoglobin, hematocrit, or RBC count. No thrombosis risk. This is a major safety advantage over full EPO.
Standard protocol: 2–4 mg subcutaneous injection 2–3 times weekly. Conservative start: 1–2 mg twice weekly, titrate upward based on tolerance and response. Onset of pain relief is rapid (days), making dose titration possible without lengthy waiting periods.
Minimal. Most common: mild injection site reactions (redness, swelling). Rare: transient headache, mild flu-like symptoms within 24–48 hours post-injection. No serious adverse events in clinical trials. No hematologic, hepatic, or renal toxicity. Safe for long-term use (within evidence limits).
Not yet. ARA-290 is in clinical development (Phase 2 trials in some indications). It's not currently approved for human use in the USA. All use is strictly for research and educational purposes. Consult a licensed healthcare professional before considering any research protocol.
Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. The compounds discussed are research chemicals that are not FDA-approved for human use. Always consult a licensed healthcare professional before considering any peptide protocol. WolveStack has no medical staff and does not diagnose, treat, or prescribe. See our full disclaimer.